<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148574</url>
  </required_header>
  <id_info>
    <org_study_id>IUM</org_study_id>
    <nct_id>NCT03148574</nct_id>
  </id_info>
  <brief_title>Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery</brief_title>
  <official_title>Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery to Reduce Intraoperative and Postoperative Blood Loss: A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bleeding is still the major cause of mortality and morbidity in postpartum period. World
      health organization has reported 585000 deaths for pregnancy each year. Twenty five percent
      of cases die from post-partum bleeding. Mean amount of blood lost is 500 ml during normal
      vaginal delivery, 1000 ml in cesarean section, and 3500 ml during cesarean section with
      emergency hysterectomy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of intraoperative blood loss</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intrauterine 400 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous infusion 10 units</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>intrauterine tablets</description>
    <arm_group_label>misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1-Uncomplicated pregnancy, 2-Had no hypersensitivity or contraindications to
        prostaglandins.

        3-Had no history of coagulopathy. 4-Accepting to participate in the study.

        Exclusion Criteria:

        \1-women with anemia (Haemoglobin &lt;8 gram ). 2 placental abnormality (e.g placenta
        previa,placenta abruption ) 3. History of complications at previous pregnancy especially
        postpartum hemorrhage. 4- Maternal hypertension , current or previous history of heart
        disease ,liver ,Renal disorders or known coagulopathy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Abbas, MD</last_name>
      <phone>00201003385183</phone>
      <email>bmr90@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>November 11, 2017</last_update_submitted>
  <last_update_submitted_qc>November 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

